$RVMD News

RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $182

HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $195

Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $195

Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs

Bernstein Initiates Coverage On Revolution Medicines with Market Perform Rating, Announces Price Target of $151

Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation

Is Daraxonrasib’s Phase 3 Pancreatic Cancer Data And EQRx Deal Altering The Investment Case For Revolution Medicines (RVMD)?

Needham Keeps Buy Rating on Revolution Medicines (RVMD) Despite Wider Loss

Truist Securities Assumes Revolution Medicines at Buy, Raises Price Target to $179

Assessing Revolution Medicines (RVMD) Valuation After A Powerful Multi Year Shareholder Return Run

Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report

$100 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today

Revolution Medicines (RVMD) Receives FDA’s “Safe to Proceed” Letter for Daraxonrasib

Is It Too Late To Consider Revolution Medicines (RVMD) After A 240% One Year Surge?

RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $165

Revolution Medicines, Inc. Q1 2026 Earnings Call Summary

Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $165

Piper Sandler Maintains Overweight on Revolution Medicines, Raises Price Target to $172

Needham Maintains Buy on Revolution Medicines, Lowers Price Target to $183

Revolution Medicines Q1 Earnings Call Highlights